Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

xin at 60 mg/m(2). We are optimistic that the 75 mg/m(2) cohort of this Phase 2 trial will be fully enrolled by year-end, and we look forward to reporting additional efficacy and safety data later this year."

Data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in ovarian cancer were presented today during the Gynecologic Cancer: Ovarian Cancer session in a poster titled "A Phase 2 Trial of Voreloxin (formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer" (Abstract #5582). A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. In addition to the ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer, voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeloid leukemia (AML) patients, and in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therape
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Qualcomm Incorporated ... subsidiary, Qualcomm Life, Inc., is collaborating ... chronic care management solutions powered by Qualcomm Life,s ... Platform to enable continuous care, informed interventions and ... announced at Qualcomm Life,s annual Connect 2015 ...
(Date:8/31/2015)... 31, 2015  AMRI (NASDAQ: AMRI ) ... collaboration focused on the development, manufacture and marketing ... ("APIs"). The collaboration combines Saneca,s strength in extracting ... developing and manufacturing controlled substance APIs with AMRI,s ... processes into these facilities. The collaboration will also ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
Breaking Medicine Technology:Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4
... The Food and Drug Administration says 12 brand ... abuse, overdoses, addiction, and even deaths across the U.S. ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Find ... Sign up for e-mail notices of new FDA Consumer ...
... HILL, N.C., April 19, 2011 The oncology market ... biopharmaceutical industry, but managing all the aspects of successfully ... global strategic marketing functions supporting the oncology therapeutic area ... to run a high-performing group. Best Practices, ...
Cached Medicine Technology:Oncology Global Strategic Marketing Study Offers Chance for Resource Benchmarks 2
(Date:8/31/2015)... ... August 31, 2015 , ... ... services, and others—to hold down costs? , In a commentary for The ... HealthReveal, presents the concept of “clinical efficacy,” which would bind parties together in ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
(Date:8/31/2015)... ... August 31, 2015 , ... The dental implant and prosthetic market ... Academy of Implant Dentistry. (See Press Room ) More than 30 million Americans ... procedure. With the increasing demand for dental implants, the National Association of Dental Laboratories ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, son ... ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, but ... National Call Center and website since Aug. 17. , The Greens have operated ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo , a leader in the ... in the 3rd quarter, the newly re-styled and re-designed “Hallmark Series” updates the Passport ... These new models include more glass and a more upscale feel than the current ...
Breaking Medicine News(10 mins):Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Dental Association Raises Awareness as Implant Industry Grows 2Health News:Dental Association Raises Awareness as Implant Industry Grows 3Health News:Dental Association Raises Awareness as Implant Industry Grows 4Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Finnleo Introduces Hallmark Series Saunas 2
... Oct. 30 TeleHealth Services, Inc., a,leading provider ... named Matthew K. Barker to the new position ... strategic market planning,market research and analysis., After ... direct its marketing efforts for its comprehensive line ...
... Monday, November 3, 2008, ALEXANDRIA, Va., Oct. 30 ... filed an amicus brief in support of a,courageous Vermont ... for the amputation of her gangrenous arm caused by ... with the wholehearted backing of the Food and Drug,Administration ...
... FAIRFIELD, N.J., Oct. 30 Arno Therapeutics,Inc. (OTC ... oncology therapeutics, today announced the appointment,of William F. ... as chairman of,the audit committee. Dr. Hamilton has ... Wharton School with particular expertise in the areas ...
... surge in cases of depression based on financial woes, ... mental health,professionals will convene at the San Diego Convention ... Congress amid a deepening economic,crisis causing new waves of ... annual Congress runs through Sunday. More than 100 sessions,and ...
... by Dr. David Katz, Director of Yale University,s,Prevention Research Center ... in Blood Pressure -, DERBY, Conn., Oct.30 Snacking ... help with weight control, according to a recently,completed pilot study ... overweight adults consumed two KIND Fruit & Nut Delight,Bars per ...
... Inc. (Nasdaq: BDMS ), operators of PERFECT ... review third quarter 2008 results. In,addition to third ... expectations of future financial and operating,results. The call ... at 9:00 a.m.,MT., Dial in to 1-866-282-2517; ...
Cached Medicine News:Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:The Senior Citizens League's Comments on U.S. Supreme Court Case Wyeth v. Levine 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3Health News:Psychiatric Congress Opens Amid Growing Climate of Economy-Driven Anxieties 2Health News:Psychiatric Congress Opens Amid Growing Climate of Economy-Driven Anxieties 3Health News:Daily Snack Bars May Facilitate Weight Loss 2Health News:Daily Snack Bars May Facilitate Weight Loss 3Health News:Daily Snack Bars May Facilitate Weight Loss 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: